Glenmede Trust Co. NA trimmed its position in shares of Alkermes plc (NASDAQ: ALKS) by 8.4% during t

Alkermes plc (ALKS) Q2 2026 Earnings Call Transcript

ALKS posts break-even Q2 earnings and tops revenue estimates as product sales surge, with Lumryz add

Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the q

Alkermes NASDAQ: ALKS reported second-quarter 2026 revenue of $496 million, supported by growth acro

Alkermes (ALKS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarte

Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings bea

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast present

Needham analyst Ami Fadia maintains Alkermes (NASDAQ:ALKS) with a Buy and raises the price target

Alkermes reports positive long-term data for alixorexton, showing sustained wakefulness and symptom

Alkermes plc (NASDAQ:ALKS) today announced results from a planned interim analysis of the ongoing lo

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced results from a planned interim

On July 6, 2026, Alkermes plc (the "Company") and Amneal Pharmaceuticals LLC ("Amneal&#3

Top Wall Street analysts changed outlook on top stocks. See all changes including upgrades, downgrad

After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs

On June 23, 2026, Alkermes PLC (ALKS) shares rose 4.3% today, bringing the current price to $48.06.

Alkermes plc maintains a Buy rating, driven by the accretive Avadel Pharmaceuticals acquisition and

Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax t

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced detailed positive results from

Alkermes wins orphan drug designations in the United States and Europe for alixorexton for treating

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that alixorexton, a novel, inve

With AI and space dominating many of the market's most popular investment themes, it can be difficul

Alkermes NASDAQ: ALKS executives said the company is entering a period of heightened execution as it

Alkermes plc (ALKS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcri

On June 09, 2026, Alkermes PLC (ALKS) shares rose 4.4% today, bringing the current price to $44.28.

US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen

Four Roses, Six Flags, and Trump's potential Quantum investments: This week's deal activity

Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerati

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earning

Companies Reporting Before The Bell • Deutsche Bank (NYSE:DB) is estimated to report quarterly earn

Companies Reporting Before The Bell • GSK (NYSE:GSK) is estimated to report quarterly earnings at $

Companies Reporting Before The Bell • Teck Resources (NYSE:TECK) is expected to report quarterly ea

Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fisc

Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for i

  Companies Reporting Before The Bell • Deutsche Bank (NYSE:DB) is projected to report earnings fo

  Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is projected to report quarterly loss